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AbstrAct
Autophagy is a self-degradative physiological process by which the cell removes 
worn-out or damaged components. Constant at basal level it may become highly 
active in response to cellular stress. The type 2 transglutaminase (TG2), which 
accumulates under stressful cell conditions, plays an important role in the regulation 
of autophagy and cells lacking this enzyme display impaired autophagy/mitophagy 
and a consequent shift their metabolism to glycolysis. To further define the molecular 
partners of TG2 involved in these cellular processes, we analysed the TG2 interactome 
under normal and starved conditions discovering that TG2 interacts with various 
proteins belonging to different functional categories. Herein we show that TG2 
interacts with pyruvate kinase M2 (PKM2), a rate limiting enzyme of glycolysis which 
is responsible for maintaining a glycolytic phenotype in malignant cells and displays 
non metabolic functions, including transcriptional co-activation and protein kinase 
activity. Interestingly, the ablation of PKM2 led to the decrease of intracellular TG2’s 
transamidating activity paralleled by an increase of its tyrosine phosphorylation. 
Along with this, a significant decrease of ULK1 and Beclin1 was also recorded, thus 
suggesting a block in the upstream regulation of autophagosome formation. These 
data suggest that the PKM2/TG2 interplay plays an important role in the regulation 
of autophagy in particular under cellular stressful conditions such as those displayed 
by cancer cells.
INtrODUctION 
TG2 is a unique pleiotropic enzyme belonging 
to the family of transglutaminase which catalyses 
post-translational modifications of proteins through 
Ca2+ dependent reactions including protein–protein 
crosslinking, incorporation of primary amines into 
proteins, as well as glutamine deamination [1-3]. TG2 
is the most ubiquitous and widely distributed isoform 
in tissues and cell types. It is predominantly a cytosolic 
protein but is also present in mitochondria, nucleus, on 
the plasma membrane and in the extracellular matrix 
under pathological settings [4-6]. Under steady state 
conditions, TG2 is in a closed (compact) conformation, 
upon stress stimuli, its Ca2+ dependent activation shifts 
TG2 to undergo a conformational change (open) and it 
becomes catalytically active as a transamidating enzyme 
[7, 8]. In addition to protein transamidation, TG2 displays 
other enzymatic activities, which do not require Ca2+ such 
as GTPase, protein kinase, and protein disulfide isomerase 
(PDI) activity [9-11]. More recently, the PDI activity of 
TG2 has been shown to regulate mitochondrial function 
[12]. In fact, our group has provided the first evidences 
showing that TG2 contributes to the correct assembly 
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table 1: the list of tG2 interacting proteins under normal and autophagic conditions. 
NORMAL
Rank Protein Name Accession No. 
Total 
Ion 
Score
Total 
Ion 
C.I.%
HSPA1A protein [Homo sapiens] gi|14424588 2748 100
Tubulin, beta 2 [Homo sapiens] gi|12654709 1.657   100   
Tubulin alpha 6 [Homo sapiens] gi|15080013 1.444   100   
tubulin alpha-1 chain - human gi|2119266 1.420   100   
tubulin beta gi|223429 1.072   100   
heat shock 10kDa protein 1-like [Homo sapiens] gi|55962550 1.001   100   
TUBA8 [Homo sapiens] gi|47678731 966   100   
dnaK-type molecular chaperone HSPA6 - human gi|87626 813   100   
heat shock protein 90-alpha - human gi|72219 738   100   
solute carrier family 25 (mitochondrial carrier\; adenine nucleotide translocator), member 
6 [Homo sapiens] gi|57162659 634   100   
beta-tubulin 4Q [Homo sapiens] gi|16974658 579   100   
heat shock 70kDa protein 9B precursor [Homo sapiens] gi|24234688 560   100   
BAG2 [Homo sapiens] gi|49065418 428   100   
DnaJ protein homolog [Homo sapiens] gi|219588 416   100   
similar to Chain , Heat-Shock Cognate 70kd Protein (44kd Atpase N-Terminal Fragment) 
(E.C.3.6.1.3) gi|51095055 407   100   
DnaJ (Hsp40) homolog, subfamily C, member 7 [Homo sapiens] gi|4507713 348   100   
EEF1A1 protein [Homo sapiens] gi|48735185 311   100   
BiP protein [Homo sapiens] gi|6470150 290   100   
glyceraldehyde-3-phosphate dehydrogenase [Homo sapiens] gi|31645 237   100   
Similar to ATP synthase, H+ transporting, mitochondrial  F1 complex, alpha subunit, 
isoform 1 gi|13938339 213   100   
stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein) [Homo sapiens] gi|54696884 171   100   
TSG101 gi|48425523 187   100   
enigma protein isoform 1 [Homo sapiens] gi|11496885 163   100   
PKM2 protein [Homo sapiens] gi|34782802 141   100   
enigma - human gi|627429 123   100   
AUTOPHAGY
Rank Protein Name Accession No. 
Total 
Ion 
Score
Total 
Ion 
C.I.%
Tubulin, beta 2 [Homo sapiens] gi|12654709 452   100   
Tubulin alpha 6 [Homo sapiens] gi|15080013 386   100   
TUBA8 [Homo sapiens] gi|47678731 377   100   
TUBB [Homo sapiens] gi|49456871 336   100   
solute carrier family 25, member 5 [Homo sapiens] gi|4502099 308   100   
tubulin beta chain - human gi|71584 300   100   
ADP.ATP translocase gi|339723 294   100   
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 
4 [Homo sapiens] gi|55749577 267   100   
EEF1A1 protein [Homo sapiens] gi|48735185 83 100
The complex of TG2 and its interacting partners was separated by HPLC and identified by mass spectrometry.
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of the respiratory chain complexes [13]. The absence 
of TG2´s PDI activity leads to incorrect assembly of 
mitochondrial ADP/ATP transporter adenine nucleotide 
translocator 1 (ANT1) [14]. ANT1 is the most abundant 
protein in mitochondria and catalyses the exchange of 
mitochondrial ATP for cytosolic ADP [15]. Additionally, 
due to its multifunctional nature, TG2 is involved in the 
regulation of numerous cell functions, including cell 
death/survival and autophagy [16, 17] and many TG2 
substrates have also been identified both in vitro and/or 
in vivo [18-20]. 
Autophagy is an essential homeostatic process that 
delivers cytoplasmic constituents to the lysosome. As a 
result, it is able to clear long-lived proteins, aggregates, 
organelles such as mitochondria, ER, peroxisomes and 
possibly bacteria and viruses [21-24]. Even though there 
is an ongoing basal autophagy in the cell, autophagy 
is rapidly activated in response to stress, e.g. nutrient 
deprivation, hypoxia and pressure overload to catabolize 
cellular substrates and generate energy [21-24]. In fact, 
metabolites released from lysosomes are involved in 
regulation of cellular homeostasis and energy production 
[25]. This suggests an essential role for autophagy in 
energy homeostasis. Defects in the autophagy machinery 
have been associated to the pathogenesis of many diseases 
including neurodegenerative, heart and liver disorders and 
cancer [22-23, 26-27]. Previous studies in our and other 
groups have proposed a role of TG2 in autophagy [28-
30]. Particularly, TG2 and its transamidating activity have 
shown to be important for a proper autophagic degradation 
[28-29]. It has also been proposed that TG2 is involved 
in the formation and clearance of ubiquitinated protein 
aggregates characterizing diseases affecting both the brain 
and the liver [4, 31]. Additionally, a very recent study in 
our group has shown that TG2 ablation leads to mitophagy 
impairments and, in order to survive, the cells lacking this 
enzyme display a higher rate of aerobic glycolysis [32]. 
This important metabolic change suggests a role for the 
enzyme in the regulation of the cellular metabolism from 
mitochondrial respiration to aerobic glycolysis, which is 
typically detected in transformed cancer cells [33]. 
On these bases we decided to further investigate the 
molecular mechanisms by which TG2 is involved in these 
cellular processes by identifying its interactome under 
normal and autophagic conditions. 
rEsULts
characterization of tG2 interactome under 
normal and autophagic conditions
In order to identify the TG2’s binding partners, we 
carried out the enzyme interactome analysis under steady 
state and autophagic conditions (induced by starvation for 
2 hours) by utilizing TAP approach combined with HPLC 
and MALDI TOF/TOF mass spectrometry. TAP method 
involves the fusion of a TAP tag to the target protein and 
its expression in a host cell or organism [34]. The TAP-
tagged protein, as well as its associated partners, is purified 
from cell extracts by two specific affinity purification/
elution steps. Flag-hemagglutinin (HA)-tagged TG2 was 
expressed in human fibroblast 2fTGH cells (Figure S1A 
and S1D). 2fTGH cells transfected with untagged TG2 
served as a negative control (Figure S1B). Western blot 
analysis for TG2 and sypro staining confirmed that TAP 
was performed successfully as there were no HA-Flag 
bands detected in control conditions (Figure S1B and 
S1C). During autophagy TG2 is acting as a transamidating 
enzyme assuming its open conformation versus the closed 
one present in cells under normal steady state conditions 
[28]; considering this, our analysis will also define the 
enzyme’s protein partners associated to these two different 
3D configurations. 
Our interactome analysis has revealed that TG2 
interacts with various proteins belonging to different 
functional categories such as chaperones, mitochondria, 
metabolism and cytoskeleton (Figure S2). Particularly, 
out of all categories, 39% and 50% are proteins related 
to chaperone protein family. In addition, we found a 
significant reduction in the number of TG2 interacting 
proteins in cells undergoing autophagy (Table 1). 
However, the interactions with chaperones are still 
observed. Interestingly, we have found that TG2 interacts 
with a well-defined group of proteins involved in the 
clearance of misfolded and toxic/mutated proteins. 
Among these, particularly interesting is a group of 
chaperones participating in the handling of proteins such 
as HSP10, HSP40, HSPA1A, HSP90, DnaJ and BAG2 
(Table 1), some of which are components of chaperone 
mediated autophagy (CMA) and chaperone-assisted 
specific autophagy (CASA) [35-36]. In addition, we have 
identified the interaction of TG2 with some mitochondrial 
proteins such as the ATP synthase, ANT and Pyruvate 
Kinase M2 (PKM2), which is a rate limiting enzyme of 
glycolysis [37]. 
Validation of tG2 interactome
TG2 and its interacting partners identified in this 
study are part of a very large network (Figure 1). It is 
interesting to note that TG2 interacts with a network of 
chaperone proteins (highlighted in boxes) that are involved 
in the protein handling machinery, thus suggesting an 
important role for TG2 in proteostasis. Therefore, in order 
to confirm that TG2 interacts with the putative novel 
partners identified by the TAP approach, we analysed 
by co-immunoprecipitation (co-IP) the interaction of the 
enzyme with some proteins reported in the interactome 
list (Table 1) such as HSPA1A, a molecular chaperone; 
PKM2, involved in the glycolytic pathway; Hsc70 and 
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EEF1A1, two important mediators of CMA [35, 38-40]. 
Since the interactome analysis indicated a role for TG2 
in proteostasis, we decided to treat 2fTGH cells with 
MG132, a specific inhibitor of proteasome that is known 
to induce a cellular stress associated to the accumulation 
of misfolded ubiquitinated proteins (Figure 2A), as well 
as with nutrients deprivation (Starv), which leads to 
autophagy induction. The results confirmed that TG2 
co-immunoprecipitates with all the above mentioned 
proteins (Figure 2B-2E). Our co-IP analysis also shows 
that the interaction of TG2 with these protein substrates is 
already detectable in basal conditions with the exception 
of HSPA1A, thus confirming the interactome data. On the 
other hand, upon starvation, TG2 interacts with HSPA1A, 
Hsc70 and EEF1A1, while its interaction with PKM2 
is diminished upon autophagy induction (Figure 2B). 
Interestingly, for all the analysed proteins the stronger 
interaction with TG2 is detected under proteostasis stress 
induced blocking the proteasome by MG132. 
PKM2 regulates the transamidating activity of 
tG2
It has been shown that cells lacking TG2 display 
an impaired mitochondrial function associated to an 
increase in their aerobic glycolysis and become sensitive 
to the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) 
[32]. Based on these findings we decided to focus our 
attention on PKM2. To understand the biological role of 
the TG2/PKM2 interaction, we first performed the RNA 
interference for PKM2 in 2fTGH cells and analysed the 
expression of TG2. PKM2 knockdown was successful 
as indicated by the western blotting analysis (Figure 3A 
and 3B). Considering that the absence of PKM2 causes 
alterations in glycolysis pathway [37], we asked how 
PKM2 down-regulation affects the overall cell metabolism. 
We therefore measured the lactate concentration, as 
an indicator of the glycolytic flux, in 2fTGH cell lines 
in the presence and absence of PKM2. Lack of PKM2 
resulted in significantly less glycolytic activity that in 
turn caused a decrease in the acidification of the culture 
medium (Figure S3). In keeping with these findings we 
detected a marked reduction in the level of HIF1, a key 
regulator of glycolysis (Figure 3A and 3B) [41]. In order 
to verify whether the PKM2 ablation and the consequent 
glycolysis inhibition had any effect on TG2, we monitored 
the enzyme’s transamidating activity upon autophagy 
induction by using rapamycin, a well-known lipophilic 
macrolide antibiotic which is widely used to induce 
autophagy by inactivating mTOR, and 2-DG a glycolysis 
inhibitor. To this aim, we used BAP incorporation assay 
to detect the intracellular TG2’s transamidating activity. 
Intracellular TG2 is known to be inactive under steady 
state conditions and activated upon stressful stimuli, which 
lead to the accumulation of free Ca2+ inside the cytoplasm 
[7, 8]. Figure 3C clearly indicates a net decrease of the 
intracellular enzyme’s transamidating activity after 4 
Figure 1: schematic representation of the tG2 interactome. The proteins in black were obtained from our TAP analysis while 
the ones in red were added after screening the protein/protein interaction databases. Proteins in boxes are involved in the clearance of 
ubiquitinated proteins.
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hours of rapamycin treatment in the absence of PKM2 
with no effect observed by the treatment with 2-DG. 
To confirm the effect of the PKM2 ablation on TG2’s 
transamidating activity we monitored the crosslinking 
activity in cells starved for 24 and 48h (Figure 3D). Taken 
together these results demonstrate the marked inhibitory 
effect displayed by PKM2 ablation on the increase of the 
TG2’s transamidating activity (Figure 3E) observed upon 
autophagy induction with both rapamycin and starvation 
(Figure 3C and 3D). 
In order to have an insight on the molecular 
mechanisms by which PKM2 regulates the TG2’s 
transamidating activity, we examined the TG2 
phosphorylation upon PKM2 ablation (Figure 3F). To 
this aim we immunoprecipitated TG2 in 2fTGH cells 
in which PKM2 was silenced by siRNA and the level 
of tyrosine-phosphorylated enzyme was detected by 
western blot analysis using a phospho-tyrosine antibody. 
The results reported in Figure 3F clearly indicated that, 
upon silencing of PKM2, there is a marked increase in the 
phospho-tyrosine staining of TG2 compared to the control, 
thus suggesting that the decreased TG2’s transamidating 
activity correlates with an increased in its tyrosine post-
translational modification.
Downregulation of PKM2 leads to autophagy 
impairment
Previous studies have shown that the TG2 
transamidating activity is involved in the last stages of 
autophagy [28-29]. On the other hand, we and others have 
demonstrated that PKM2 is involved in the regulation of 
HIF1 expression [42-43] and according to this, a decreased 
glycolysis has been linked to a decreased expression of 
HIF1 and autophagy inhibition [41]. Considering the 
above reported effect of PKM2 on TG2, we decided to 
verify whether PKM2 knockdown could also affect 
Figure 2: tG2 interacts with PKM2, HsPA1A, Hsc70 and EEF1A1 in Flag-HA-tG2 2ftGH cells. A. Immunoblotting 
analysis of ubiquitinated proteins in 2fTGH cells. Cells were subjected to starvation in presence or absence of MG132 for 4 h, and ubiquitin 
expression levels were assayed by immunoblotting with anti-ubiquitin antibody. Actin was used as loading control. Immunoblotting analysis 
of b. anti-PKM2 immunoprecipitation (IP), c. anti-HSPA1A IP, D. anti-Hsc70 IP and E. anti-EEF1A1 IP in Flag-HA-TG2 overexpressing 
2fTGH cells. Cells were subjected to immunoprecipitation, using the indicated antibodies, under steady state condition, after 4h of starvation 
and upon proteasome inhibition by using MG132 for 4 h. WC, whole cell lysate, was used as a protein control.
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autophagy. Therefore, we first monitored autophagy after 
PKM2 inhibition by analysing the expression levels of 
Beclin1 and ULK1, two key proteins involved in the early 
stages of autophagosome formation [44]. Figures 4A and 
4B clearly show that in the absence of PKM2 there is a 
significant decrease of Beclin1 and ULK1 suggesting 
impairment in the early step of autophagosome formation. 
To verify this hypothesis, we decided to better characterize 
the autophagic process in the presence and absence of 
PKM2 by monitoring p62 (Figure 4C), an autophagy cargo 
protein that is itself degraded by autophagy and functions 
to deliver ubiquitinated proteins to the phagophore 
by binding directly to LC3 and thus enabling their 
degradation in the lysosome [45-47]. Interestingly, the 
Figure 3: Analysis of tG2 transamidating activity and PKM2 protein expression levels. A. Immunoblotting analysis of 
PKM2, TG2 and HIF1-beta in 2fTGH cells. Knockdown of PKM2 was performed by RNA interference for 72 h, as described in Material 
and Methods. Actin was used as a loading control. b. Densitometric analysis of blots (quantification of PKM2, TG2 and HIF1-beta bands 
normalized to actin levels). Data are expressed as mean ± SD, n = 4 independent experiments. Statistical significance refers to the respective 
control (*p<0.05 and ***p<0.0001). (C-D) Immunoblotting analysis of the TG-catalysed incorporation of BAP in 2fTGH cells in the 
presence and absence of PKM2. The cells were labelled with BAP and treated with 2-DG or Rapamycin for 4 h c. or subjected to starvation 
for 24 and 48 hours D. GAPDH was used as a loading control. E. Immunoblotting analysis of the TG-catalysed incorporation of BAP in 
2fTGH cells. The cells were labelled with BAP and subjected to starvation for 24 h in absence or presence of ZDON. Cells not labelled with 
BAP were used as negative control.  GAPDH was used as a loading control. F. Immunoblotting analysis of anti-TG2 immunoprecipitation 
in 2fTGH cells. PKM2 was knocked-down by RNA interference for 72 h as described in Materials and Methods, and cells were subjected to 
immunoprecipitation in steady conditions and upon proteasome inhibition with MG132 for 4 h. Anti-phosphotyrosine (p-Tyr) was used to 
reveal the presence of phosphorylated TG2 (left panel). Anti-TG2 was used to visualize immunoprecipitated TG2 (right panel). WC, whole 
cell lysate, was used as a protein control.
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inhibition of PKM2 resulted in significant accumulation of 
p62 thus confirming a possible inhibition in the autophagic 
process (Figure 4C) [45]. 
Autophagy is the major mechanism to eliminate 
damaged organelles and we have recently demonstrated 
that TG2, by its transamidating activity, is also involved in 
the removal of damaged mitochondria by this process [32]. 
Considering the above reported autophagy impairment 
associated with the absence of PKM2, we decided to verify 
whether mitophagy might be affected as well. For this 
aim, we treated 2fTGH cells expressing different levels of 
PKM2 with the mitochondrial uncoupler carbonyl cyanide 
m-chlorophenyl hydrazine (CCCP) for 18 h and measured 
their relative mitochondrial mass by Mito Tracker Green 
(MTG) staining and flow cytometry analysis. As shown in 
Figure 4D, the cells with down-regulated PKM2 exhibit a 
significant increase in mitochondrial mass compared to the 
controls, confirming that the PKM2-dependent impairment 
of autophagy also leads to a defective clearance of 
mitochondria. 
Loss of PKM2 leads to a defect in autophagic flux
In order to get an insight into PKM2’s role in the 
autophagic process, we decided to investigate the effect 
of its ablation in 2fTGH cells overexpressing GFP-
LC3, which is widely used as a marker for autophagic 
vesicles [47]. To detect the autophagic flux we also 
analysed these cells in the presence and in the absence of 
Figure 4: PKM2 inhibition leads to an autophagy impairment. A. Immunoblotting analysis of Beclin1 and ULK1 in 2fTGH cells 
after RNA interference for PKM2. Actin was used as a loading control. b. Densitometric analysis of blots (quantification of Beclin1 and 
ULK1 bands normalized to Actin levels). Data are expressed as mean ± SD, n = 4 independent experiments. Statistical significance refers 
to the respective control (*p<0.05 and ***p<0.0001). c. Immunoblotting analysis of p62 in 2fTGH cell line in the presence and absence 
of PKM2 and densitometric analysis of blots (quantification of p62 bands normalized to Actin levels). Data are expressed as mean ± SD, 
n = 4 independent experiments. Statistical significance refers to the respective control (*p<0.05). Actin was used as a loading control. D. 
Mitochondrial mass was evaluated in 2fTGH cell lines in the presence and absence of PKM2 by MTG staining and quantified by FACS. 
Quantification of MTG mean fluorescence intensity is referred as percentage of a control value. Data are expressed as mean ± SD, n = 3 
independent experiments. Statistical significance refers to the respective control (*p<0.05). 
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NH4Cl. As clearly shown in Figure 5A, in the absence of 
PKM2, GFP-LC3 dots decreased compared to the control 
samples. This finding is further confirmed by blocking 
the autophagy flux by NH4Cl that leads to an increased 
number of dots only in the control cells, further indicating 
a defect in autophagy in the absence of PKM2. These 
results were confirmed by the western blot analysis of the 
LC3II levels observed upon ablation of PKM2 by siRNA 
in cells treated with NH4Cl. In fact, the results reported 
in Figure 5B show that upon blockade of the lysosomal 
activity by NH4Cl, the cells lacking PKM2 display a 
significative reduction in the autophagic flux as indicated 
by the decreased accumulation of LC3II upon NH4Cl 
treatment. 
DIscUssION
The results of this study confirmed the complexity 
of the biological role played by TG2. The analysis of 
the enzyme’s proteome has revealed that TG2 interacts 
with various categories of proteins of which the most 
represented is a well-defined group of chaperones involved 
in proteostasis. The composition both in terms of number 
of proteins detected and the categories represented is 
largely reduced upon induction of autophagy. Interestingly, 
the comparative analysis of the two interactomes also 
reflects that, upon induction of autophagy, TG2 is in its 
transamidating-prone open conformation while under 
steady state conditions the enzyme is inactive and is 
Figure 5: Immunofluorescence analysis of autophagy in the presence and absence of PKM2. A. Analysis of autophagic 
flux in GFP-LC3 overexpressing 2fTGH cells and in the presence of NH4Cl, which inhibits the activation of the lysosomal enzymes, 
hence blocking the degradation process of LC3 II isoform. Green dots represent autophagosomes, nuclei were stained with Hoechst 33342 
(blue). b. Immunoblotting analysis of LC3 in 2fTGH cells starved for 2 h and 4 h in EBSS or treated with 20 mM NH4CI for 4 h after 
RNA interference for PKM2. Proteins were analysed by immunoblotting using anti-LC3 (left panel). Densitometric analysis of blots 
(quantification LC3 II bands normalized to Actin levels). Data are expressed as mean ± SD, n = 4 independent experiments. Statistical 
significance refers to the respective control (**p<0.001) (right panel).
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present in its close conformation [8]. 
It is also important to mention that previous 
studies reported some of the proteins we detected 
in the interactome as TG2 substrates or interactors 
(tubulin, actin, ANT and gyceraldehyde-3-phosphate 
dehydrogenase) thus validating that the TG2 partners 
reported in this study are bona fide enzyme’s specific 
interacting proteins [14, 48-49]. Interestingly, previous 
studies have revealed that TG2 is a fundamental 
component for proper maturation of autophagosomes and 
that TG2 ablation results in mitophagy impairment and a 
shift to high levels of glycolysis indicating an alteration in 
the mitochondrial metabolism [29, 32]. Our interactome 
analysis demonstrated that TG2 interacts with PKM2, 
which is a key rate limiting enzyme controlling the cellular 
glycolytic activity [50]. 
Regulation of PKM2 activity by tyrosine kinase 
signalling is important for metabolic changes that 
support proliferative metabolism and tumor growth in 
several contexts [50]. In line with this finding, previous 
studies have shown that TG2 interacts with Fructose-
1,6-bisphosphate aldolase, glyceraldehyde-3-phosphate 
dehydrogenase, alpha-ketoglutarate dehydrogenase, 
phospho-glycerate dehydrogenase and fatty acid synthase 
which are involved in energy metabolism [51-52]. All 
these findings suggest a role for TG2 in the regulation 
of energy homeostasis. Interestingly, our data show that 
the PKM2 inhibition causes a blockage in autophagy. 
It has been well documented that tumor cells activate 
autophagy in response to a variety of stresses [53-54]. 
Indeed, inhibition of PKM2 leads to a significant reduction 
in the expression of early regulators of autophagy such 
as and ULK1 and Beclin1 associated to a decrease in 
LC3II processing and consequently an impairment of the 
autophagic flux as also demonstrated by accumulation 
of p62. In keeping with these findings PKM2 inhibition 
also leads to a significant reduction in the expression 
of HIF1, a well-known positive regulator of autophagy 
[41]. Interestingly, it has been shown that dimeric 
PKM2 localizes to the nucleus, where by acting as a 
protein kinase activates STAT3 [55-56]. Nuclear STAT3 
modulates autophagy via the transcriptional regulation 
of several autophagy-related genes, such as BCL2, 
BECN1, PIK3C3, HIF1, BNIP3, and various microRNAs, 
including the MIR17HG that regulates both ULK1 and 
Beclin1 [57-58]. These findings strongly support our data 
showing that the ablation of PKM2 leads to autophagy 
impairment characterized by Beclin1, ULK1, HIF1 protein 
downregulation. Interestingly, the down-regulation of 
PKM2 leads to a marked decrease of TG2 transamidating 
activity indicating that PKM2 is able to stimulate TG2 
cross-linking activity that is required for the proper 
maturation of autophagosomes [29, 32]. Thus, under 
steady state conditions PKM2 might positively regulate 
autophagy by modulating, either directly or indirectly, 
the TG2’s transamidating activity. In keeping with this 
assumption, it is interesting to note that, in the absence of 
PKM2, we observed an increased TG2’s phosphorylation 
on tyrosine residues. Thus this indicates that PKM2 
negatively regulates a tyrosine kinase(s) that are able to 
post-translationally modify TG2. Based on these results 
it is possible to hypothesize that the negative regulation 
carried out by TG2 on glycolysis involves its interaction 
with PKM2. In conclusion, this study has highlighted for 
the first time an important homeostatic control linking 
autophagy to glycolysis, which is dependent by the relative 
expression levels of PKM2 and its interplay with TG2. 
Future studies should further define the exact molecular 
events regulating this important cellular metabolic switch 
which is a typical hallmark of cancer cells. It is important 
to note that the modulation of autophagy has been shown 
to have high therapeutical impact in tumor treatment [59-
62].
MAtErIALs AND MEtHODs
Antibodies
The following antibodies were used: anti-TG2 
(Thermo Scientific, CUB7402), anti-PKM2 (Cell 
Signalling, D78A4), anti-EEF1A1 (Milipore, 05-235), 
anti-Hsc70 (Abcam, 51052), HSPA1A (Santa Cruz, 7947), 
anti-Biotin (Abcam, 1227), anti-p62/SQSTM1 (mbl, 
PM045), anti-LC3 (Novus Biologicals, NB100-2331), 
anti-GAPDH (Sigma, G9545), anti-Actin (Sigma, 2066), 
anti-Beclin1 (Santa Cruz, 10086), anti-HIF1-beta (Novus 
Biologicals, NB100-124), anti-ULK1(Santa Cruz, 33182), 
anti-phospho-tyrosine (Cell Signaling, 9411) and HRP-
conjugated secondary antibodies (Bio-Rad Laboratories). 
cell culture, transfection and drug treatments
2fTGH (human fibrosarcoma), Flag-HA-TG2 
2fTGH, GFP-LC3 2fTGH and RFP-GFP-LC3 2fTGH 
cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (Lonza) supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, 100 μg/ml streptomycin and 
100 units/ml penicillin at 37°C. For generation of the TG2 
stably expressing cells (Flag-HA-TG2 2fTGH), 2fTGH 
cells were transfected with pLPCX-TG2-HA-Flag using 
CaCl2 method. Autophagy was induced by using 1 μM 
rapamycin (Rapam, Sigma-Aldrich) or 10 mM 2-deoxy-
D-glucose (2-DG, Sigma-Aldrich). For amino acids 
starvation (Starv), cells were washed twice in the amino-
acid-free medium Earle’s Balanced Salt Solution (EBSS) 
(Sigma-Aldrich) and incubated in the same medium for 
the indicated periods. In order to inhibit autophagy, cells 
were incubated in full medium with 20 mM ammonium 
chloride (NH4Cl, Sigma-Aldrich) for the indicated period. 
For proteasome inhibition, cells were incubated with 5 μM 
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MG132 (Z-Leu-Leu-Leu-al; Sigma Aldrich) for 4 h. To 
induce mitochondrial damage, cells were incubated in full 
medium with 15 μM carbonyl cyanide m-chrolorophenyl 
hydrazine (CCCP, Sigma-Aldrich). TG2 transamidating 
activity was inhibited by incubating the cells with 40 
μM Z-DON (Zedira) for 24 hours, concomitantly with 
starvation. 
cloning of tGase 2 gene with HA and Flag tag
HA tagged TG2 was obtained by polymerase chain 
reaction (PCR) amplification using pLPCX-TG2 vector. 
The construct was cloned into the XhoI and EcoRI sites 
of the pLPCX-TG2 vector. Second, pLPCX-TG2-HA 
plasmid was used as a template to produce dual tag. The 
construct was inserted into the NotI and Xhol sites of the 
template. The plasmid containing full length human TG2 
tagged with HA and Flag was transformed and sequenced 
to verify the amplification. Primers used for plasmid 
construction of TG2 HA-Flag are shown in Figure S1D.
retrovirus generation and infection
5 mg of an expression plasmid (pLPCX TG2-HA-
Flag) was co-transfected with 15 μg of the retroviral vector 
into HEK293 gp/bsr using the calcium phosphate method. 
After 48 h, the supernatant containing the retroviral 
particles was collected and supplemented with polybrene 
(4 µg/ml). 2fTGH cell lines were infected with retroviral-
containing supernatant for 6–8 h.
Tandem Affinity Purification (TAP)
Cell lysates were prepared in lysis buffer (10 mM 
Tris, 50 mM NaCl, 10% glycerol, 0.5% NP40) and 
protease inhibitors. The lysates were pre-cleared by using 
IgG beads for 45 min and incubated with 200 μl Flag 
agarose beads for 2 h and washed extensively. To elute 
the bound proteins, the supernatant was incubated with 
Flag peptide for 30 min at 4°C and centrifuged again. The 
eluted complex was reincubated with 100 μl HA agarose 
beads for 2 h and washed 5 times with 1 ml Tris/NP40. 
The final protein complex was eluted with 100 µl Glycine 
(100 mM, pH: 2.4). 10 µl of Tris-Cl (1 M, pH: 8.0) was 
immediately added to neutralize the effect of glycine. The 
complex containing TG2 and its interacting proteins were 
separated by HPLC and identified in mass spectrometry.
Gel sypro
The gel was (1) fixed in 10% methanol: 7% ethanoic 
acid for 30 min with continuous rocking; (2) incubated 
over-night with Sypro Stain (RubyTM Gel Stain 1X, 
BioRad); (3) washed in Fixer solution and in deionized 
water for 30 min and then visualised at Typhoon scanner.
Liquid sample processing for HPLc analysis
The purified complexes of TG2 with its interacting 
partners obtained from TAP were boiled for 5 min at 
100°C to denature the proteins and expose the hidden sites 
to trypsin action. The disulphide bonds were reduced with 
10 mM dithiothreitol at 56°C for 30 min, and alkylated 
with 55 mM iodoacetamide at room temperature for 20 
min. The samples were then precipitated in 80% ethanol 
and incubated over-night at -80°C. 
The following day, the samples were centrifuged 
at 4000 g at 10°C for 40 min. The protein pellet was 
resuspended in a solution of 50 mM ammonium 
bicarbonate at room temperature. The samples were 
digested by trypsin (200 ng) at 37°C for 12 h, purified 
through the filter of a Zip-Tip (C-18 Resin, Millipore) and 
eluted from the Zip-Tip with 80% acetonitrile and 0.1% 
TFA. To eliminate the excess of acetonitrile, speedvac was 
used for 3 min and resuspended in 7 μl of 2.5% acetonitrile 
and 0.1% TFA. The digested peptides were separated 
through the HPLC by their different hydrophobicity and 
spotted on a MALDI plate. 
MALDI-mass spectrometry
MALDI-mass spectrometry (MS) and MALDI-
MS/MS were performed on an Applied Biosystems 
4700 Proteomics Analyzer with TOF/TOF ion optics 
(Applied Biosystems, Foster City, CA, USA). Spectra 
were calibrated externally using five peaks of standard 
(ABI4700 Calibration Mixture; Applied Biosystems) or 
internally using porcine trypsin autolysis peptide peaks. 
In addition to peptide mass finger spectra, the five most 
abundant pre-cursor ions masses having a signal-to-
noise ratio >50 were chosen for MS/MS fragmentation. 
The interpretation of both the MS and MS/MS data were 
carried out with the GPS Explorer software (version 3.6; 
Applied Biosystems). Peaks were extracted from raw 
spectra by the GPS Explorer software. A combined MS 
peptide fingerprint and MS/MS peptide sequencing search 
was performed against the NCBI non-redundant database 
without taxon restriction using the MASCOT search 
algorithm. MS/MS peptide spectra with a minimum ion 
score confidence interval ≥95% were accepted; this was 
equivalent to a median ion score cut-off of approximately 
35 in the data set. Protein identifications were accepted 
with a statistically significant MASCOT protein search 
score ≥76 that corresponded to an error probability of 
P<0.05 in our data set.
Oncotarget44951www.impactjournals.com/oncotarget
Immunoblotting
Cells were collected in a lysis buffer containing 
20 mM Tris-HCl pH 7.4, 150 mM NaCl and 1% Triton 
X-100 with protease inhibitor cocktail (Roche). Proteins 
were quantified by standard Bradford staining and 
separated using SDS polyacrylamide gels. Nitrocellulose 
membranes were used for transfer and blots were blocked 
in 5% non-fat dry milk for 1 h at room temperature and 
then incubated overnight with the primary antibodies. 
The membranes were incubated with HRP conjugated 
secondary antibody for 1 h at room temperature and the 
signal was detected by Immun-Star WesternC Kit (Bio-
Rad Laboratories).
co-immunoprecipitation assays
The cells were harvested with a lysis buffer (10 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 10 % Glycerol, 0.5% 
NP40 and proteases inhibitors), incubated at 4°C for 30 
min and centrifuged at 15000 g for 10 min at 4°C. The 
lysates were incubated with IgG beads for 45 min for pre-
clearing. The supernatants were incubated with anti-TG2 
antibody overnight in rotation. The following day, the 
complex solution were incubated with IgG beads for 45 
min and then centrifuged. The precipitate was eluted with 
35 µl of sample buffer 2X including β-mercaptaethanol, 
boiled at 95°C and used for western blot. Immunoblot 
analysis was performed with indicated antibodies.
rNA interference
siRNA oligos corresponding to the human PKM2 
were from Gene Script. 200000 cells per well were 
transfected with 10 nM final concentration of siRNA 
by Lipofectamine 2000 (Invitrogen) according to the 
manufacturer´s supply. After 72 h of transfection, cells 
were collected in lysis buffer. The RNA interference was 
checked by western blot.
In situ tG assay
In situ TG activity was measured by incorporation 
of 5-(biotinamido)pentylamines (BAP) into protein 
substrates. 2 mM BAP (Soltec Ventures, B110) were 
directly added into the medium together with the indicated 
treatments. In the presence of TG2 transamidating activity, 
BAP is incorporated into the substrates. To measure this 
activity, cells were lysed as above described and proteins 
were resolved by SDS-polyacrylamide gel. The blots were 
performed as above mentioned and anti-Biotin antibody 
was used as a primary antibody.
confocal microscopy
GFP-LC3 2fTGH, grown on coverslips, were fixed 
in 4% paraformaldehyde for 10 min and washed with 
PBS three times. Nuclei were stained with 10 mg/ml 
Hoechst 33342 for 10 min. The coverslips were mounted 
in antifade (Fluorogel with Dapco, Eletron Microscopy 
Sciences) and examined under a confocal laser scanner 
microscope (Olympus FV 1000).
Detecting of lactate levels
Colorimetric Lactate Assay Kit (Abcam) was 
used to measure lactate. The assay was performed in 
96-well plate, according to manufacturer’s instructions. 
The reaction was incubated for 30 min at RT (protected 
from light) and measured using a 96-well plate reader at 
absorbance 570 nm.
Analysis of mitochondrial mass
Mitochondrial mass was measured by Mito Tracker 
Green (MTG, Molecular Probes) staining. Cells were 
trypsinized, washed and resuspended in PBS with 100 
nM MTG for 30 min at 37°C. Fluorescence was measured 
by FACScan flow cytometer (BD Biosciences) using the 
CellQuest software (BD). In each analysis, 10000 events 
were recorded.
statistical analysis
Densitometry measurements were used for statistical 
analysis using Graph Pad. Statistical significance was 
determined using the Student’s t test; p<0.05 was 
considered significant.
Abbreviations
 2-DG, 2-deoxy-D-glucose; BAP, 5-(biotinamido)
pentylamine, 2fTGH, human fibroblasts; MTG, Mito 
Tracker Green; TG2, Transglutaminase 2; pyruvate kinase 
M2, PKM2. 
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